WO1996021422A1 - Compositions cosmetiques anhydres contenant des agents actifs sur le plan dermatologique - Google Patents
Compositions cosmetiques anhydres contenant des agents actifs sur le plan dermatologique Download PDFInfo
- Publication number
- WO1996021422A1 WO1996021422A1 PCT/US1996/001560 US9601560W WO9621422A1 WO 1996021422 A1 WO1996021422 A1 WO 1996021422A1 US 9601560 W US9601560 W US 9601560W WO 9621422 A1 WO9621422 A1 WO 9621422A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cosmetic
- cosmetic composition
- agent
- carrier
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 164
- 239000002537 cosmetic Substances 0.000 title claims abstract description 145
- 239000013543 active substance Substances 0.000 title claims abstract description 81
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims abstract description 52
- 229940061720 alpha hydroxy acid Drugs 0.000 claims abstract description 50
- 239000002245 particle Substances 0.000 claims abstract description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000011187 glycerol Nutrition 0.000 claims abstract description 15
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 12
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 210000003491 skin Anatomy 0.000 claims description 85
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 60
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 51
- 239000004005 microsphere Substances 0.000 claims description 48
- 239000002253 acid Substances 0.000 claims description 36
- 239000012071 phase Substances 0.000 claims description 35
- 239000004310 lactic acid Substances 0.000 claims description 30
- 235000014655 lactic acid Nutrition 0.000 claims description 30
- 230000002209 hydrophobic effect Effects 0.000 claims description 28
- 239000001993 wax Substances 0.000 claims description 27
- 239000004615 ingredient Substances 0.000 claims description 26
- 239000003981 vehicle Substances 0.000 claims description 25
- -1 polyethylene Polymers 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 24
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical group O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 claims description 23
- 229920000299 Nylon 12 Polymers 0.000 claims description 23
- 150000007513 acids Chemical class 0.000 claims description 23
- 235000013399 edible fruits Nutrition 0.000 claims description 23
- 239000003349 gelling agent Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004909 Moisturizer Substances 0.000 claims description 18
- 230000001333 moisturizer Effects 0.000 claims description 18
- 239000000344 soap Substances 0.000 claims description 15
- 239000002250 absorbent Substances 0.000 claims description 13
- 230000002745 absorbent Effects 0.000 claims description 13
- 239000003623 enhancer Substances 0.000 claims description 13
- 229920001296 polysiloxane Polymers 0.000 claims description 13
- 239000011148 porous material Substances 0.000 claims description 13
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical group C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 12
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 11
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- 229940086555 cyclomethicone Drugs 0.000 claims description 10
- 229940008099 dimethicone Drugs 0.000 claims description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 7
- 239000000440 bentonite Substances 0.000 claims description 7
- 229910000278 bentonite Inorganic materials 0.000 claims description 7
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical group O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229940085262 cetyl dimethicone Drugs 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 6
- 235000012211 aluminium silicate Nutrition 0.000 claims description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004200 microcrystalline wax Substances 0.000 claims description 6
- 235000019808 microcrystalline wax Nutrition 0.000 claims description 6
- 229940098697 zinc laurate Drugs 0.000 claims description 6
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 claims description 6
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 5
- 239000008407 cosmetic solvent Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 5
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 5
- 210000000434 stratum corneum Anatomy 0.000 claims description 5
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 claims description 4
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 4
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 239000012185 ceresin wax Substances 0.000 claims description 4
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 4
- 239000010445 mica Substances 0.000 claims description 4
- 229910052618 mica group Inorganic materials 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 229940057429 sorbitan isostearate Drugs 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- 239000004164 Wax ester Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 235000019386 wax ester Nutrition 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003212 astringent agent Substances 0.000 claims description 2
- 239000007844 bleaching agent Substances 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 230000001530 keratinolytic effect Effects 0.000 claims description 2
- 239000003410 keratolytic agent Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920000131 polyvinylidene Polymers 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims 1
- AIOCLJDAYKBSTO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 AIOCLJDAYKBSTO-UHFFFAOYSA-N 0.000 claims 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 claims 1
- CXIISRLRZRAKST-UHFFFAOYSA-N 29‐(4‐nonylphenoxy)‐3,6,9,12,15,18,21,24,27‐ nonaoxanonacosan‐1‐ol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 CXIISRLRZRAKST-UHFFFAOYSA-N 0.000 claims 1
- 229910052582 BN Inorganic materials 0.000 claims 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 claims 1
- 208000001840 Dandruff Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 235000012241 calcium silicate Nutrition 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 239000000551 dentifrice Substances 0.000 claims 1
- 239000002781 deodorant agent Substances 0.000 claims 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims 1
- 150000002194 fatty esters Chemical class 0.000 claims 1
- 229940088638 glycereth-7 Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 150000003893 lactate salts Chemical class 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 229940073555 nonoxynol-10 Drugs 0.000 claims 1
- 229920004906 octoxynol-11 Polymers 0.000 claims 1
- 229940032066 peg-4 dilaurate Drugs 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 229920002050 silicone resin Polymers 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 239000002798 polar solvent Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 230000006870 function Effects 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 210000000744 eyelid Anatomy 0.000 description 15
- 230000006872 improvement Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010040954 Skin wrinkling Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000033316 Acquired hemophilia A Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000003605 opacifier Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000037393 skin firmness Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940049918 linoleate Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 2
- 229920001748 polybutylene Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical class CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Chemical class 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- HVYQZCLEPABLCN-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;methyl 2-methylprop-2-enoate;prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C HVYQZCLEPABLCN-UHFFFAOYSA-N 0.000 description 1
- VHWSRELATOUTAG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-aminobenzoate Chemical compound NC1=CC=CC=C1C(=O)OCC(O)CO VHWSRELATOUTAG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- VIWIWXKTPWZMEW-UHFFFAOYSA-N 2-hydroxypropanoic acid;propane-1,2,3-triol Chemical compound CC(O)C(O)=O.OCC(O)CO VIWIWXKTPWZMEW-UHFFFAOYSA-N 0.000 description 1
- QMIBDVOQOZDSEN-UHFFFAOYSA-N 2-phenylbenzimidazole-2-sulfonic acid Chemical compound N1=C2C=CC=CC2=NC1(S(=O)(=O)O)C1=CC=CC=C1 QMIBDVOQOZDSEN-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 235000003901 Crambe Nutrition 0.000 description 1
- 241000220246 Crambe <angiosperm> Species 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical class CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001616 Polymacon Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Chemical class CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- HJXPPCPJEYUQFQ-HNNXBMFYSA-N dodecyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H]1CCC(=O)N1 HJXPPCPJEYUQFQ-HNNXBMFYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 229910052744 lithium Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940032044 quaternium-18 Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/31—Anhydrous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- compositions of the invention relate to cosmetic compositions including delivery systems that provide new ways of delivering dermatologically active agents to cosmetically significant areas of the stratum corneum.
- Compositions of the invention are particularly, but not exclusively, useful as eye enhancers to provide cosmetic benefits to eye areas such as the eyelids, under eye areas and to the canthus or outer eye corner and are also useful for cosmetic treatment of the lips and other topical areas.
- the invention includes novel film-forming systems to assist delivery of the active agent. These film-forming systems yield supplementary enhancements and are useful independently of the delivery system.
- BACKGROUND The eyes themselves are the focus of any person's identity and personality as well as a focal point of attention for others. In any face-to-face encounter, the eyes provide a powerful medium of unspoken communication. The appearance of the eyelids and facial areas around the eyes is critical to the appearance of the eyes, and hence to the impression one person receives of another. Accordingly, eye-treatment compositions comprise an important segment of the cosmetics industry.
- the eyes are cosmetically a sensitive and sometimes difficult area to treat. They are subject to congenital defects, deficiencies and disorders and the appearance of the eye areas can quickly deteriorate owing to aging, the effects of weather, diet and so on. Quality cosmetic treatment of eye areas can bring great visual and psychological benefits to an individual by making striking improvements in their appearance.
- Some common eye area problems include wrinkling, cracking, formation of fine lines, blotching and discoloration. These problems may blemish the upper and lower eyelids, particularly the under eye area and also the corners of the eye, especially the outer corner known as “the canthus” that are prone to form cracks and lines, often inelegantly referenced as “crow's feet”.
- the cosmetics industry has offered a wide range of remedies to conceal, fill, color or otherwise modulate the appearance of unattractive eye areas.
- Mascaras, eyeliners and other eyelash treatments are used to enhance and define the appearance of the eyelashes, eyebrows and the edges of the eyelids and can have a beneficial and sometimes theatrical impact on the eyes as a whole.
- More significant to the purposes of the present invention are cosmetics used for treating the major dermal areas in the vicinity of the eye, notably the eyelids, the under-eye area and the outer eye corner areas.
- Such cosmetics are eye shadows, eye creams, and eyeliners.
- general use cosmetics such as foundations and makeups can be used in the eye area, caution is needed because of the risk of contaminating the eye with stinging or irritating allergenic ingredients or of inducing swelling or bacterial infection.
- Eye cosmetics can be difficult to apply smoothly or evenly, or may have an unpleasant or tacky feel, or poor film-forming capabilities (being hard to spread) , or have high drag or may be difficult to remove. Few eye cosmetics provide long term structural dermatological improvements, except for special-purpose eye creams and moisturizers, containing skin revitalizing ingredients. Generally, such eye creams are intended for use at night and will not hold eye shadow satisfactorily so that they cannot be used for normal daytime wear because they do not provide significant enhancement of appearance.
- M dermatologically active is used herein to describe materials that act on the skin to provide a long term improvement of one kind or another, being an improvement that endures or begins after the cosmetic makeup is removed.
- dermatological activity is to be distinguished from cosmetic properties that are only effective while the cosmetic is present on the skin.
- alpha hydroxy carbolic acids of relatively low molecular weight, for example with 10 carbon or less.
- alpha hydroxy acids these acids are known to have a number of useful effects on the skin.
- Referenced “AH ⁇ 's” herein which is a common abbreviation in both the popular press and the technical literature, alpha hydroxy acids can moisturize dry skin and improve various disorders including acne and psoriasis and other skin anomalies.
- AH ⁇ 's are also effective in revitalizing the skin. Depending upon the concentration and length of application they can cause, or stimulate, exfoliation which is the removal of outer keratinous or horny tissue layers, and stimulate renewal of new skin layers to provide a significant improvement in the appearance of the skin.
- Some AHA's that have been, used to provide these benefits are the simplest alpha hydroxy acid, namely glycolic acid, as well as lactic acid, citric acid and malic acid. These acids are also known as “fruit acids” because they are found in fruits and in the case of glycolic acid, in sugar cane. There are many other AHA's, or equivalent alpha keto acids and the like, that are known, or have been suggested for use in revitalizing skin or otherwise providing useful dermatological skin functions. Some beta hydroxy acids, for example salicylic acid, also have useful dermatological properties. Some such "skin acids” are disclosed in Yu et al . U.S. Patent No. 5,091,171 the disclosure of which is hereby incorporated herein by reference thereto.
- AHA's of interest are usually quite hydrophilic, dissolve readily in water and, in the case of lactic acid become liquid around room temperature (about 16.8 °C) .
- Such hydrophilicity is usually incompatible with common hydrophobic eye cosmetics such as eye shadows, or eye primers.
- the anhydrous nature of such eye cosmetics means that small quantities of active hydrophilic agents for example ⁇ H ⁇ 's may either lose their activity due to chemical or physico-chemical combination, or fail to be delivered to the skin surface in an adequately hydrophilic or aqueous environment to be effective.
- preferred environments for such agents are significantly acidic, a condition which is difficult to provide at skin surfaces treated with anhydrous, or substantially hydrophobic, cosmetics.
- a critical problem with any eye cosmetic is to avoid irritation of, or stimulation of allergic or pathogenic reactions in the eye.
- AHA's can be very acidic and are known to be significantly irritating, even when applied to durable areas of the skin. Avoiding irritation is of special significance to products intended for daily use, in the eye or other sensitive skin areas.
- One way of delivering dermatologically or cosmetically active agents in a cosmetic vehicle is by containing the active agents in or on a suitable particulate carrier.
- a suitable particulate carrier Of particular interest for use as a carrier are small porous polymeric particles or microspheres.
- a problem with this approach is that having employed an affinity between a medium containing the active agent and the microsphere to O 96/21422 PO7US96/01560
- the active agent loaded into the microsphere, it is then necessary to overcome that affinity to release the active agent. It is also important that the delivery vehicle not possess a greater affinity for the dermatologically active agent than does the carrier, otherwise the active agent may discharge prematurely from the porous carrier into the vehicle and be dissipated.
- U.S. Patent 5,292,512 discloses a cosmetic composition for topical application in which dermatologically active agents such as acne treatments, for example retinoids and benzoyl peroxide, hormones, antifungal, antibiotics and so on are absorbed on carrier particles for delivery to the skin.
- dermatologically active agents such as acne treatments, for example retinoids and benzoyl peroxide, hormones, antifungal, antibiotics and so on are absorbed on carrier particles for delivery to the skin.
- Typical carrier particles are organic polymeric microspheres. Active products are introduced into the microspheres by dissolving them in a suitable solvent such as water, glycerol or the like (column 4 lines 47-54) .
- Schaefer et al The objective of Schaefer et al . is to deliver the active products into the sebaceous follicles for release beneath the epidermis. To this end Schaefer et al . employs rather small microspheres of which 80% have a diameter of between 3 ⁇ m and 10 ⁇ m which is apparently of an appropriate size to travel into the follicles past the epidermus. (See column 1 line 45 to column 2 line 40.) Schaefer et al . provides no 96/21422 PCIYUS96/01560
- Schaefer et al . 's loaded microspheres are formulated in various hydrophilic or hydrophobic gel compositions and are reported to provide excellent antiacne properties, presumably due to the penetration of the active ingredient loaded carrier particles into sebaceous follicles.
- Schaefer et al . 's compositions are clearly intended as single purpose preparations providing improved delivery of a specified active agent and lack independent cosmetic benefits. If the user wants to obtain cosmetic benefits additional to acne or other therapeutic treatments, a cosmetic preparation will need to be applied separately which cosmetic may be incompatible with the acne treatment.
- Schaefer et al . do not attempt to incorporate active-agent-loaded microspheres into a cosmetic base or to address the problems that may arise in doing so.
- the invention as claimed, is intended to provide a remedy. It solves the problem of how to deliver a dermatologically active hydrophilic agent to eye and other sensitive skin surface areas in an essentially hydrophobic cosmetic composition.
- the invention provides a cosmetic composition in which a dermatologically active hydrophilic agent constituted in a liquid hydrophilic medium is either adsorbed or absorbed into or onto a suitable particulate carrier.
- This carrier-active-agent system can be incorporated into a substantially anhydrous cosmetic base, for example cream suspension.
- the anhydrous base preferably comprises one or more film-forming agents to provide a novel cosmetic composition which can be topically applied to deliver the hydrophilic agent to the skin.
- Preferred embodiments of the invention provide solutions to the problem of providing a useful cosmetic composition containing an effective concentration of a dermatologically active agent which can provide controlled release of the dermatologically active agent to the skin.
- Cosmetic compositions according to the invention can be formulated into a wide range of cosmetics products, for example, pigmented eye shadows, non-pigmented eye shadow primers, lipsticks, moisturizers, lip treatments, foundations, and the like. These new cosmetics products in addition to having valuable cosmetic properties, have dermatological activity and provide lasting benefits.
- an eye shadow can be formulated with a skin revitalizing agent, for example an alpha hydroxy acid, to provide both immediate and long-term improvements to the eye lids.
- the hydrophobicity of the vehicle should tend to inhibit the hydrophilic active medium from egressing from the microsphere. While not being bound by any particular theory, it is a concept of the invention that the spreading and massaging actions that normally accompany topical application of the product act to bring AHA-loaded microspheres into contact with the skin where skin moisture draws the AHA-containing hydrophilic medium out of the microspheres.
- the cosmetic compositions of the invention are applied to particular skin areas, such as around the eyes and on the lips, they are subject to a constant kneading action as the eyelids are blinked and the lips are moved or wiped, providing continual turnover of the microspheres contacting the skin surface, and replenishment of the AHA-containing hydrophilic medium supplied to that surface.
- the film- forming nature of the anhydrous base produces a water-loss barrier on the skin's surface inhibiting transpiration of water from the skin.
- This control of water loss enables the upper cutaneous level of the skin to increase its water content thereby promoting the egress of the dermatologically active agent from the carrier into the skin.
- any water or other suitable solvent for the dermatologically active agent that is introduced by subsequent application of a secondary cosmetic product using the inventive composition as a primer can also assist the egress of the active agent from the carrier to the s.kin.
- Organic polymeric microsphere tend to be slippery and do not adhere to the skin. Strong adhesive properties can be provided to the microspheres by incorporating them into anhydrous cosmetic compositions containing suitable film- forming agents, including novel film-forming systems pursuant to the invention. When such a film system is used in cosmetic compositions containing microspheres, a good anhydrous film can be obtained with excellent spreadability and no tackiness or drag.
- Fine lines in the skin can be both cosmetically masked or concealed by a filling and light-diffusing action of the microspheres while also being dermatologically reduced by a skin revitalization action of the AHA's.
- Preferred formulations can also diffuse light to reduce the appearance of dark circles beneath the eyes and provide a soft focus effect.
- Preferred embodiments of the invention can also enhance the water barrier properties of skin surfaces to which they are applied, potentially promoting the action of dermatologically active hydrophilic agents delivered through the cosmetic and increasing the durability of cosmetics applied over- the inventive product.
- Preferred embodiments of the invention relate to novel cosmetic compositions containing an effective quantity of a polar dermatologically active agent, a sufficient quantity of suitable adsorbing or absorbing carrier to support the dermatologically active agent and one or more film-forming agents in a substantially anhydrous vehicle or base formulated to deliver the dermatologically active agent to the surface of the stratum corneum.
- This composition provides properties which enables a wearer or user to enjoy their usual, cosmetically assisted, attractive appearance while, at the same time, gaining one or more dermatological benefits which will endure after removal of the cosmetic.
- the essentially or substantionally anhydrous base provides a medium or vehicle for dispersal of the active-agent loaded carrier particles which medium can be liquid or semi-solid, for example, a dispersant or solvent for other cosmetic ingredients bringing desired cosmetic properties to the composition.
- the anhydrous base can thus comprise a more or less volatile hydrophobic cosmetic solvent in which a gelling agent is optionally dispersed to provide a desired consistency.
- Suitable carrier materials include but are not limited to polymeric organic microspheres and inorganic particulates.
- Some commercially available microspherical powders useful in the preparation of the cosmetic materials of this invention include organic polymeric materials for example polyethylene, polypropylene and copolymers thereof, polyurethane, polyesters, polya ides, poly ethylmethacrylate, nylon, ethylene acrylates copolymers and polyvinylidene copolymers.
- Substantially any non-toxic, non-irritating, cosmetically compatible organic polymeric material that can be provided in a satisfactorily adsorbent or absorbent form for the purposes of this invention, and which is compatible with the anhydrous vehicle, can be used.
- inorganic particulates include talc, clays, organic modified clays, kaolin, mica, calcium salicylate and various carbonates of various metals, for example calcium and magnesium.
- the carrier particles should not be too large or their presence as a component of the composition will be apparent to the user and may give a particulate coarse or sandy, rather than, smooth feel to the cosmetic.
- at least eighty percent of the particles should not exceed 50 and preferably not exceed 20 microns.
- the particles should be too small, or they may be absorbed in the sebaceous follicles, which is not desired, and will provide too small a storage volume for the passenger dermatologically active agent.
- the carrier particles should be relatively large to be able to release passenger active from either the surface or through surface openings from interior volumes of the particles.
- at least eighty percent of the carrier particles are in excess of 10 microns in diameter.
- a particularly preferred range for at least eighty percent of the particles is from 10 to 20 microns, more preferably from 10 to 15 microns.
- a useful average particle size is from 12 to 20 microns.
- a porous carrier particle is particularly preferred whereby a liquid phase can be absorbed within the particle to occupy, for example, from 10 to 90 percent of the particle's volume, rather than simply being retained on the particle's surface.
- An absorbent matrix powder serving as a carrier for topical delivery of the dermatologically active agent or dermatologically active solution can comprise porous synthetic organic polymeric microspheres, for example a cosmetically acceptable polyamide such as nylon 12, in a proportion of from about 0.1 to about 40.0 percent, preferably from about 5.0 to about 20.0 percent, and more preferably from about 6.5 to about 10.0 percent by weight of the cosmetic composition.
- the organic polymeric microspheres impart desirable feel properties for example creamy, powdery and silky qualities to consumer formulations, and enhance the light-scattering qualities of the formulation.
- the organic polymeric microspheres When discharged of AHA or other dermatologically active agents the organic polymeric microspheres are available to absorb skin oils, helping control oil breakthrough.
- Dermatologically Active Agents examples include, but are not limited to, the following: anesthetics, for example, benzyl alcohol, lidocaine and menthol; astringents, for example, witch hazel, benzoic acid and aluminum or aluminum/zirconium salts; keratolytics, for example resorcinol, salicylic acid, ascorbic acid and acetic acid; exfoliants, for example, lactic acid, glycolic acid and other alpha or beta hydroxy acids; vasoconstrictors, for example, phenylepinephine hydrochloride; external analgesics, for example, tripelenna ine hydrochloride and camphor; anti-inflammatory agents, for example, salts of glycyrrhizic acid, alpha bisabolol; salicylate derivatives and ibuprofen; anti-irritants, for example, allantoin, proteins
- anesthetics for example, benzyl alcohol, lidocaine
- the active material is to be absorbed onto or absorbed into a particulate carrier which in turn is dispersed in an essentially anhydrous cosmetic base or vehicle, it is preferred that the dermatologically active agent or ingredient be polar and have little or no affinity for the components of the essentially anhydrous base.
- One or more dermatologically active agents in a range of from about 0.01 to about 10.0 percent by weight of the composition can be incorporated into preferred embodiments of the current composition. More preferably these agents can be added from about 0.5 to about 8.0 percent and still more preferably from about 1.0 to about 5.0 percent. Other active agents can be used in equivalent proportions depending upon their activity however proportions are preferred in the sensitive eye area.
- Preferred dermatologically active agents are classes of exfoliants known as alpha and beta hydroxy acids respectively. These materials can be used to both moisturize and revitalize the skin resulting in better structural and visual qualities. These benefits may begin to be apparent only after long-term use of the cosmetic composition of the invention on a regular, for example daily, basis for a period of from days to weeks, for example, beginning at fourteen or twenty-one days and continuing until from three to six months of daily or twice daily applications or even continuing indefinitely.
- the novel, substantially anhydrous eye or lip cosmetic composition of this embodiment of the invention contains, as dermatologically active hydrophilic agent, at least one alpha hydroxy acid (“AHA” herein) , for example lactic acid, citric, malic, mixed fruit acids, or mixtures thereof, supported on a matrix, or in a porous particulate carrier.
- AHA alpha hydroxy acid
- the AHA is preferably supported on the carrier particles so as to be present in surface pores of the carrier particles and also in interior pores communicating with those surface pores, whereby the AHA bearing hydrophilic medium can be released at the particle surface and withdrawn from the carrier particle by skin moisture, possibly by capillary action.
- alpha hydroxy acids which can be used in practicing this invention include a straight or branched chain aliphatic acid with not more than three substituents in the aliphatic backbone, said substituents being non-basic and being selected from the group consisting of hydroxy, aldehyde, keto, carboxyl, chloro and nitro. Acidity and water or hydroalcoholic solubility are desirable characteristics of the alpha hydroxy acids used in the present invention.
- Some preferred alpha hydroxy acids contain at least one hydrophobic moiety being a carbon atom having four substantially non-polar bonds for example carbon-carbon or carbon-hydrogen bonds. Such hydrophobicity is believed useful to balance the electronegative hydroxy and carboxyl radicals for improved biological compatibility and efficiency.
- alpha hydroxy aliphatic acids are preferably nonocarboxylic acids selected from the group consisting of 2-hydroxy-n-butanoic acid, 2-hydroxy-isobutanoic, 2-hydroxy- n-pentanoic, 2-hydroxy-isopentanoic, 2-hydroxy-n-hexanoic acid, 2-hydroxy-isohexanoic acid.
- Di- or polyhydric analogs thereof can also be used, for example, 2,X-dihydroxy analogs thereof where "X" is an integer from 3 to 6, as appropriate for the respective monohydroxy acid, indicating the carbon atom location of a second hydroxyl substituent in a carbon atom other than the number one or two carbon atoms.
- such dihydroxy acids balance the additional electronegativity attributable to the second hydroxyl with a further hydrophobic moiety as described above.
- the solvent system should have little or no affinity for the essentially anhydrous base. This is important to retaining both the solvent and its dermatologically active solute in or on the carrier and to preserving the intended functionality of the dermatologically active agent.
- the solvent should be suitably vicous to further help retard the migration of the dermatologically active agent from the carrier.
- the solvent should be inert or inactive with respect to, or at least not negatively impact the functionality of the dermatologically active agent.
- Hydrophilic Solvents Some classes of liquid hydrophilic solvents or disperse phase media that can be used alone or in combinations as adjuvants to assist the loading of the dermatologically active agent or agents onto or into the particular carrier include but are not limited to water, alcohols and ethers.
- a suitable class of alcohols comprises mono-, di-, tri- or polyhydroxy alcohols having the formula: (OH) I R - (CH) ⁇ - (C) v - (CH 2 ). - R 1
- R 1 H , CH 3 , O-CH j , 0 -CH 2 -CH 3
- Suitable examples of such compounds include glycerin, propylene glycol, dipropylene glycol, propanol, isopropanol, butanol, isobutanol, pentanol, isopentanol, neopentanol, diglycerol, polyglycerol, sorbitol, polyethylene glycerol, and polyol.
- Suitable ethers include unsubstituted and substituted ethers for example UCON (trademark) fluid, Union Carbide Corp. or DOWANOL (trademark) fluids, Dow Chemical Company or CARBITOL (trademark) and CELLOSOLVE (trademark) solvents from Union Carbide.
- suitable viscous, hydrophilic solvents or blends of solvents can be used with the dermatologically active agent in a proportion of from about 99 parts: 1 part to about 1 part: 99 parts.
- preferred proportions are chosen to exploit the physical or physico-chemical characteristics of the solvent to deliver the dermatologically active agent an active form in a liquid phase for uptake by absorbent carrier particles.
- major properties of solvent are preferred, for example a proportion of from about 1:1 to about 1:20 parts agent to solvent, on a weight basis.
- a preferred solvent for a dermatologically active agent for example an alpha hydroxy acid (AHA) is glycerin.
- AHA alpha hydroxy acid
- the solvent's viscosity helps retain the AHA within or on the particulate carrier while the hydrophilicity permits skin moisture to draw dissolved AHA out of or off of the microparticle.
- the invention provides for a film-forming agent to assist with the adhesion of the loaded particulate carrier onto the skin and to help form an occlusive barrier to enhance the buildup of water on or near the surface of the skin.
- film-forming is meant that an essentially continuous layer of product is formed on the surface of the skin.
- occlusive is meant that a barrier is placed on the surface of the skin which barrier substantially blocks or retards the loss of volatile materials from the skin's surface and enables them to build up in the upper layers of the skin.
- the barrier film is preferably hydrophobic.
- Suitable cosmetic film-forming agents that can be used alone or in combination include but are not limited to metallic soaps, waxes and film-forming emollients. Some non-limiting examples of each of these classes of cosmetic film-forming agents will now be described. Others will be known to those skilled in the art.
- Metallic soaps are useful materials which function to aid adhesion and to promote the formation of a hydrophobic film.
- the metallic soap gelling agent or agents can be an alkaline earth or aluminum alkanoate of from six to twenty carbon atoms, for example, the laurate, oleate, or stearate salts of calcium, magnesium, zinc, aluminum or lithium or mixtures thereof.
- a cosmetic metal soap, for example zinc laurate can be used in a proportion of from about 1.0 to about 5.0 percent, preferably about 3.0 percent by weight of the composition.
- Metallic soap functions as an ionic gelling agent, aids adhesion and adds to hydrophobic film formation.
- R-X a long chain saturated, unsaturated, cyclic or branched chain alkyl radical of from C 8 to C, 000000
- X is -H, -OR 1 or -C-OR 11 , where R 1 is H, or a saturated, unsaturated, cyclic or branched chain alkyl radical of from C,, to C ⁇ t ⁇ ; R 11 is H or residue of a mono-, di-, tri- or polyhydroxy compound capable of forming a mono-, di-, tri or polyester.
- Preferred waxes have melting points which exceed 100 °F.
- Materials such as glyceryl wax esters, beeswax, ceresin wax, carnauba wax, candelilla wax and other cosmetically acceptable waxes can be used.
- a total wax content of from 0 to 10.0 percent is adequate for formulating satisfactory cosmetics, pursuant to the invention.
- total wax content does not exceed 5.0 percent and more preferably not 3.0 percent.
- Suitable waxes are, for example, glyceryl tribehenate, ceresin wax and microcrystalline wax used in proportions of from about 0.00 to about 5.00 percent, preferably about 0.1 to 1.5 percent. More preferably from about 0.25 to 0.5 percent of waxes such as glyceryl tribehenate and a somewhat higher proportion of about 1 to 2 percent of a ceresin was are used.
- the low wax content attainable with cosmetic compositions according to the invention has the advantage of providing low drag and enhanced removability.
- Useful wax functions are adhesion, imparting a creamy feel to the product, film forming and increasing viscosity.
- Emollients useful in the present invention include those with the following formula c n H (2n + 2 . ⁇ ) , where n is an integer from 6 to greater than 1 million and x is 0 or an even integer no greater than n and may include saturated, unsaturated, branched and cyclic hydrocarbon chains. Examples include: mineral oil, petrolatum, PERMETHYL (trademark) fluids, and polybutylenes.
- Further useful film-forming emollients include the mono-, di-, tri- or poly-branched, -cyclic, -saturated or - unsaturated alkyl esters or ethers of di, tri or polyhydroxy compounds for example ethylene glycol, propylene glycol, glycerin, sorbitol or polyol.
- emollients include but are not limited to vegetable oils for example soybean oil, babassu oil, castor oil, cottonseed oil, Chinese tallow oil, crambe oil, perilla oil, Danish rapeseed oil, rice bran oil, palm oil, palm kernel oil, olive oil, linseed oil, coconut oil, sunflower oil, safflower oil, peanut oil, and corn oil.
- Preferred saturated and unsaturated vegetable oils are those having fatty acid components with 6 to 24 carbon atoms.
- Suitable emollient film-forming agents include esters of the formula:
- R.-C-OR or R.-O-C- (CH,) -C-O-R, 0 II 0 i " 0 i '
- R, and R z are saturated, unsaturated, branched or cyclic alkyl radicals of 2 to 24 carbon atoms and n is an integer from 0 to about 20.
- Silicone-based auxiliary film-forming agents may also contain a silicone material to provide some measure of auxiliary film-forming ability.
- Suitable silicone materials are preferably insoluble in water and cyclo ethicone, polyalkylsiloxanes, polyarylsiloxanes, polyalkylarylsiloxanes, polysiloxane gums, amino functional polysiloxanes and polyethersiloxane copolymers. Teachings directed to additional suitable silicone materials can be found in U.S 4,788,006; U.S. 4,341,799; 4,152,416; 3,964,500; 3,208,911; 4,364,837 and U.S. 4,465,619, the disclosures of all of which are hereby incorporated herein by reference there to.
- auxiliary film-forming agents comprises substances formed by the polymerization of alkylene oxide monomers of the formula 0 / ⁇ H(CH 2 ) n - HC - CH 2
- n is an integer from 0 to about 3.
- These materials can be either a homogeneous polymer or a copolymer of two or more monomers.
- homogeneous polymers include polypropylene oxide and polybutylene oxide. Typically, the molecular weights of these materials is between 100 and 10,000 daltons. Additionally, these materials can be condensed with a mono or polyhydroxyalkyl alcohol as exemplified by the UCON (trademark) fluids from Union Carbide Corp.
- the film-forming agent can be used alone or in combination with other film-forming agents to achieve desired aesthetic properties in the final preparation.
- a preferred range of film-forming agents is from 1 to 99%, more preferably from about 1 to 50% by weight of the composition.
- Suitable non-hardening film formers for example dimethicone, can be used in proportions of from about 0.5 to about 5.0 percent, preferably about 0.6 to 1.5 percent, and more preferably about 1.0 percent.
- Preferred functions include film forming, skin protectant or water-barrier forming agent, lubricious and silky emollient.
- Film enhancing agents for example aluminum-myristate- treated mica, in a proportion of from about 4.0 to about 20.0 percent by weight of the composition, preferably about 5.0 to 8.0 percent, and more preferably 6.5 percent can be used.
- Preferred film enhancer functions include adhesion to skin, imparting of a creamy and silky feel to the composition and enhancing hydrophobic film formation.
- the invention also provides a novel film-forming system which comprises relatively high proportions of a particulate mineral gelling agent, for example a bentonite-clay based gelling agent, and of a metallic soap gelling agent, such for example as zinc laurate, while using only a small proportion of wax, if any.
- a particulate mineral gelling agent for example a bentonite-clay based gelling agent
- a metallic soap gelling agent such for example as zinc laurate
- carrier loading of our AHA is achieved by dissolving the AHA in glycerine and absorbing the glycerine-dissolved AHA on porous microspheres or fine polymer particles.
- This system is intended for use in a hydrophobic environment where the AHAs remain in storage contained in the porous microspheres.
- microspheres When applied to the skin, as the cosmetic is rubbed or massage ⁇ into cne skin, microspheres are brushed across the skin surface, bringing them into contact with moisture which releases the hydrophilic AHA-glycerine system from the microporous polymer particles.
- the AH ⁇ is preferably loaded on the carrier particles, for example, porous nylon particles in a liquid medium which should be sufficiently viscous to be held in the particles' pores during formulation.
- Lactic acid melts at 16.8 °C and can be absorbed into porous carrier particles, without the need for any adjuvant, at temperatures above this melting point, by blending in appropriate proportions, for example, near 1:1 by weight, until the lactic acid is absorbed.
- Other acids such as a mixture of fruit acids, can be similarly loaded on to carrier particles by agitating ie. blending, by using fine powders with a sufficiently small particle size to be contained in the carrier's pores.
- the novel, substantially anhydrous eye or lip cosmetic composition of this embodiment of the invention contains, as dermatologically active hydrophilic agent, at least one AHA, for example lactic acid or mixed fruit acids, supported on a matrix, or porous particulate carrier in powder form, of a synthetic organic polymer, for example nylon.
- AHA is preferably present in surface pores of the carrier particles and also in interior pores communicating with those surface pores, so that the AHA can be released at the particle surface and withdrawn from the carrier particle by skin moisture.
- the invention also provides a low-wax, or zero-wax, cream- to-powder film-forming vehicle for the foregoing AHA-loaded system.
- This low-wax vehicle is made possible by a unique combination of a relatively high proportion of a gelling agent such as a bentonite and a high proportion of a metal soap, preferably in a volatile solvent system such as a cyclomethicone, for example dimethicone or a non-polar solvent, for example a volatile hydrocarbon.
- novel eye enhancers according to the invention are surprisingly long lasting, as shown by comparative data. Whereas traditional eye makeups may need refreshing after a few hours and are usually fading noticeably in about six hours, eye cosmetics produced according to the invention can endure satisfactorily for over 12 hours without unacceptable fading.
- Cream-to-powder products according to the invention are quick drying.
- the solvent evaporates off in a matter of a few seconds to provide a silky smooth powder film.
- Inclusion of a light- diffusing agent scatters light in the shadows between wrinkles cracks or other skin defects and helps give the product a soft focus appearance.
- Such eye enhancers pursuant to the invention work synergistically the film-forming system and AH ⁇ loaded porous microspheres to provide an enhanced appearance on application, giving the skin an illusion of improved skin quality while the alpha hydroxy acid released on contact with the skin actively conditions or revitalizes the skin, so that after a period of regular use, which may be as low as four weeks, the appearance of the skin without cosmetics is improved.
- a preferred hydrophobic vehicle for the active-agent-loaded microsphere particles is a silicone gel, which is preferably formulated using a volatile silicone solvent such as a dimethicone.
- a preferred gelling agent is a bentonite powder.
- the invention preferably employs a low wax, cosmetic film-forming system comprising, in weight percent based on the weight of the composition, from 5.0 to 13.0 percent of a particulate mineral gelling agent, for example a bentonite, and at least 1.0 percent of a metallic soap gelling agent, with no more than 5.0 percent of a cosmetic wax material, if present, dispersed in a volatile cosmetic solvent, preferably a cyclomethicone in a proportion of from about 30.0 to 70.0 percent.
- a particulate mineral gelling agent for example a bentonite
- metallic soap gelling agent preferably a metallic soap gelling agent
- a volatile solvent for example a cyclomethicone, preferably the penta er form
- a hydrophobic vehicle for example for a cream-to-powder composition.
- Suitable proportions are from about 20.0 to about 70.0 percent by weight of the composition, preferably about 30 to 40 percent, and more preferably about, 33.0 percent. Functions as a wetting agent while quickly evaporating upon application.
- a gelling agent suitable for a volatile solvent for example quaternium-18 bentonite, from about 1.0 to about 15.0 percent, more preferably from about 3 to 10 percent, and more preferably about 5.0 to 6.0 percent. Physically stabilizes the composition and functions as a pigment- suspension vehicle and to absorb oil and reduce shine.
- a wetting agent for example sorbitan isostearate, from about 1.0 to about 10.0 percent by weight of the composition, preferably about 3.5 to 4.5 percent, and more preferably about 4.0 percent can be used.
- Preferred wetting agents allow for increased capacity of solid material, and impart a hydrophobic film.
- Additional polymeric microspheres Synthetic polymeric microspheres additional to the AHA carrier powder, for example poly ethylmethacrylate, can be used in a proportion of from about 8.0 to about 20.0 percent by weight of the composition, preferably about 10.0 to 15.0 percent, and more preferably 12.0 percent. Such additional polymeric microspheres act as feel enhancers, providing a "ball bearing" feel on application, and a velvety, dry feel after application and evaporation of the solvent. Additional functions include light scattering and impartation of a powdery feel to the product.
- Oily esters An oily, low-volatility solvent ester, for example isononyl isononanoate, is useful for volatility and molecular weight control of the solvent system in a proportion of from about 1.0 to about 10.0 percent by weight, preferably from about 4.0 to 6.0 percent, and more preferably about 5.0 percent of a solvent.
- Preferred solvents also function as lipophilic emollients, aid in the solubilization of the ingredients and are miscible with the volatile carrier solvent (for example dimethicone) .
- One or more oil soluble moisturizers for example lauryl PC ⁇ , in a proportion of from about 0.4 to about 2.5 percent, preferably about 0.5 percent, or cetyl dimethicone, in a proportion of from about 1.0 to about 5.0 percent by weight of the composition, can be used to enhance moisturization. Cetyl dimethicone provides a light, dry feel and aids film formation.
- Oil absorbents Kaolin or other oil absorbents in a proportion of from about 0.50 to about 3.0 percent by weight of the composition, preferably about 0.7 to 1.5 percent, and more preferably 1.00 percent can be used. Preferred oil absorbent functions include absorption of excess skin oils, skin adhesion, light diffusion, and opacification. Opacifiers. An opacifier, for example titanium dioxide, can be used in a proportion of from about 0.10 to about 5.0 percent by weight of the composition, preferably about 0.3 to 1.0 percent, and more preferably 0.50 percent to provide coverage and help mask skin defects.
- a volatile polar activator solvent for the gellant for example hexylene glycol
- hexylene glycol can be used in a proportion of from about 0.75 to about 1.75 percent by weight of the composition, preferably about 0.85 percent. This will act as a binder plasticizing agent, solvent and softener while providing resistance to moisture and oxidation.
- Preservatives such as, for example, methyl or propyl paraben, can be used in proportions of, for example, 0.1 to 0.3 percent by weight, as is known to those skilled in the art.
- vitamin E linoleate in a percentage of about 0.10 percent as a supplemental moisturizer
- vitamin E acetate at about 0.10 percent functions as a free radical scavenger and an antioxidant
- retinyl pal itate at about 0.1 percent functions as a derivative of retinoic acid to reduce fine lines
- ceramides at a percentage below about 0.3 percent function as a skin firmer
- sphingolipids serve the function of skin firming at a percentage below about 0.3 percent, function to improve the skin's barrier thereby increasing moisturization and decreasing penetration of irritant substances.
- a class of cyclomethicone compounds that is preferred for use in the cosmetic compositions of this invention is illustrated by compounds of the formula -[R.R 2 SiO] n -, in which R and R is each lower alkyl having from one to four carbon atoms with or without innocuous substitutes selected from the group consisting of halo, hydroxyl, carboxyl or methoxy and n is from 3 to 6; which compounds are cyclized.
- the volatile cyclomethicone solvent used can be a single one of the foregoing compounds or a mixture thereof and the compound or compounds can be a homopolymer in which all n monomeric units are similar, or a heteropolymer in which they are different.
- cyclomethicones are dimethicones especially homopolymers in which n is 4 or 5; and R and R is each methyl such as octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane.
- ingredients can be used, as known to those skilled in the art, in proportions known to those skilled in the art.
- Such ingredients include, but are not limited to, fragrance, color, pigments, preservatives, wetting agents, oil absorbents, opacifiers, and antioxidants.
- Table I sets forth the ingredients used in Examples 1 and 2.
- a Glycerin 20 20 is provided.
- Example 1 porous Nylon-12 microspheres are loaded with lactic acid using a glycerin solvent. Glycerin is mixed in a blender with an equal amount of lactic acid to form phase A using the proportions set forth in Table II. Nylon-12 powder is then added to phase A in a ratio of two parts phase A to three parts Nylon-12. The glycerin lactic acid phase is substantially completely absorbed by the Nylon-12 microspheres, increasing their density, to produce a free flowing powder. This combination is blended for one hour to produce a physically stable, mildly tacky, lactic acid powder blend which is subsequently used in Example 9.
- Example 1 is repeated using mixed fruit acids in place of lactic acid in the proportions indicated in Table I. A physically stable, mildly tacky powder is obtained and used in Example 10.
- a dry mix for use in eye enhancer compositions is prepared in a single phase using the ingredients referred to in Table II. Powdered zinc laurate is combined with aluminum [ yristate] coated mica, kaolin, and titanium dioxide and blended until a smooth homogenous powder is obtained.
- Table III sets forth the ingredients used in Examples 4-5.
- porous Nylon-12 microspheres are loaded with lactic acid without the use of solvents.
- the phase A ingredient is slowly added to the phase B ingredient while mixing on a blender at room temperature.
- the preparation yields a 4:1 Nylon-12/lactic acid blend utilized in Example 7.
- Example 4 is repeated, substituting mixed fruit acids for lactic acid and reducing the proportion nylon-12 utilized, to yield a product with a 1:1 ratio of nylon-12 to mixed fruit acids. This preparation is utilized in Example 6. Table IV sets forth the ingredients used in Examples 6-8.
- Example 6 incorporates the composition prepared as in Example 5 in an anhydrous base according to the percentages listed in Table III.
- the phase B ingredients are dispersed by mixing for at least three minutes at high speed. Once -4b- dispersed, phase B is added to phase C and blended at low speed for one minute. Phase A ingredients are mixed and heated to 65 degrees Celsius until clear. When phase A is clear, the blended phase B and C mixture is added, in a propeller type mixer until uniform and free of lumps. Once this mix is uniform, phase D ingredients are added and the mix is again blended to uniformity.
- Example 6 is repeated with the addition of Nylon-12 at phase B, to further enhance the feel of the composition, and the substitution of solventless nylon-12 carrier lactic acid blend, as prepared in Example 4, for solventless nylon-12 carrier mixed fruit acid blend as prepared in Example 5.
- the acid blend substitution yields a composition with a higher percentage of alpha hydroxy acid.
- Example 8 Solventless Nylon-12/Mixed Fruit Acid Blend in an Anhydrous Base as a Color Primer
- Example 8 utilizes the procedure designated in Example 6 with the inclusion of a phase E comprising additives and colorants.
- This final phase involves the mixture being brought to 45 degrees Celsius at which point the phase E ingredients are added and blended until uniform.
- the cetyl dimethicone and dimethicone are substantially replaced with cyclomethicone.
- the less volatile cetyl dimethicone and dimethicone lead to the production of a creamy composition whereas the more volatile cyclomethicone produces a composition that will rub out into a cream to powder vehicle.
- Various coloring agents can be used as is evidenced by the inclusion of several coloring agents as phase B ingredients.
- Table V sets forth the ingredients used in Examples 9-10.
- Example 9 blends the compositions prepared in Examples 1 and 5 and adds to them the ingredients listed in Table III.
- the procedure for preparing Example 9 is that used in example 8.
- Example 9 makes use of hydrophobic sphingolipids complex to promote skin firming.
- Example 9 is repeated with the substitution of Example 2, mixed fruit acid powder blend, in place of Example 1, lactic acid powder blend.
- Physiological Benefits Controlled biophysical studies, employing the eye cosmetic composition of Examples 9 (lactic acid) and 10 (mixed fruit acids) , demonstrated valuable structural dermatological improvements. Some controlled tests showed significant increases in the moisture content of the canthus (outer eye corner) and under eye, accompanied by an increase in firmness and a reduction in fine lines and wrinkles. Twenty female subjects per product were treated in a half- face design with the products of Examples 9 and 10. The Example 9 or 10 product alone was applied around one eye and a moisturizing eye cream concentrate was applied, prior to the product, around the other eye. Treatments were applied to the face twice daily, but not on the morning on which measurements were taken. Skin moisturization, firmness and the textural characteristics of the canthus were determined, as described below.
- Example 9 the lactic acid formulation of Example 9 was more effective than the mixed fruit acid (MFA) formulation of Example 10, and the eye cream moisturizer provided a useful additional motorization benefit, at four or more weeks. Comparable, albeit slightly lower, results were obtained on the under eye, as shown in Table VII, below.
- Table IX show a significant, 16 percent increase in firmness obtained with the lactic acid formulation of Example 9, after only four weeks of use.
- the mixed fruit acid (MFA) formulation of Example 10 was somewhat less effective, but still produced a significant increase in skin firmness. Better results are obtained after six weeks and by using a moisturizer.
- compositions of the invention can be used as an eyeshadow primer to reduce eyeshadow creasing and color loss and to impart water resistance.
- Eyeshadow creasing is a well-known phenomenon frequently exhibited by people with oily skin, which displays itself as an unevenness in color, or displacement of eye shadow into ridges and furrows, that may develop within a few hours of application of eyeshadow.
- the inventive eyeshadow primer composition was applied to one eyelid only of each panelist and allowed to dry for one minute, following which a rose-colored eyeshadow was applied to both eyelids.
- the eyelids were videotaped immediately following application of eyeshadow and a picture of the center of each eyelid was frozen for image analysis. The procedure was repeated three and six hours after the first application. Image analysis showed that primer-treated eyelids exhibited insignificant increases in unevenness of the eye shadow, even after six hours. In contrast, unevenness of eyeshadow coverage increased significantly at both three and six hours on eyelids lacking primer. Eyeshadow color.
- Other tests showed that the eyeshadow primer composition of Example 9 was effective in controlling eyeshadow color loss. Neither formula changed the color of a superimposed eyeshadow, as measured with a chromameter.
- the forehead was chosen as a target site for color control tests because of difficulties in safely measuring eyelid color and because of physiological similarities between the forehead and eyelids with regard to the presence of sebum and the like.
- Eyeshadow and primer were applied to one side of the forehead of each of twelve subjects. Eyeshadow alone was applied to the other. Immediately after each application, color measurements were made with a chromameter and repeated three and six hours later.
- the color of the eyeshadow was not changed by applying it over the primer composition of the invention.
- the present invention is particularly suitable for application to modern industrial processes.
- it is useful in the cosmetics industry where it can provide new products offering new benefits to consumers, as described herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48643/96A AU4864396A (en) | 1995-01-11 | 1996-01-11 | Anhydrous cosmetic compositions with dermatologically active agents |
EP96904572A EP0802785A1 (fr) | 1995-01-11 | 1996-01-11 | Compositions cosmetiques anhydres contenant des agents actifs sur le plan dermatologique |
PL96321293A PL185239B1 (pl) | 1995-01-11 | 1996-01-11 | Zasadniczo bezwodna kompozycja kosmetyczna do miejscowego stosowania oraz sposób jej wytwarzania |
BR9607560A BR9607560A (pt) | 1995-01-11 | 1996-01-11 | Composições cométicas anidras contendo agentes dermatologicamente ativo |
UA97073757A UA56991C2 (uk) | 1995-01-11 | 1996-11-01 | Практично безводна косметична композиція для місцевого застосування (варіанти), спосіб її виготовлення, олівець для очей та косметична плівкоутворювальна система |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37122295A | 1995-01-11 | 1995-01-11 | |
US08/371,222 | 1995-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996021422A1 true WO1996021422A1 (fr) | 1996-07-18 |
Family
ID=23463028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/001560 WO1996021422A1 (fr) | 1995-01-11 | 1996-01-11 | Compositions cosmetiques anhydres contenant des agents actifs sur le plan dermatologique |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0802785A1 (fr) |
CN (1) | CN1172426A (fr) |
AR (1) | AR003918A1 (fr) |
AU (1) | AU4864396A (fr) |
BR (1) | BR9607560A (fr) |
CA (1) | CA2209657A1 (fr) |
PL (1) | PL185239B1 (fr) |
UA (1) | UA56991C2 (fr) |
WO (1) | WO1996021422A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058628A1 (fr) * | 1997-06-20 | 1998-12-30 | Mary Kay Inc. | Composition cosmetique renfermant un agent de blanchiment et un desquamant |
WO1999058104A1 (fr) * | 1998-05-12 | 1999-11-18 | Interhealth Ab | Compositions therapeutiques |
FR2788692A1 (fr) * | 1999-01-26 | 2000-07-28 | Oreal | Composition anhydre comprenant une phase particulaire et une phase huileuse comprenant de l'isononanoate d'isononyle, utilisation en cosmetique, pharmacie ou hygiene |
KR100348826B1 (ko) * | 1999-11-12 | 2002-08-17 | 주식회사 태평양 | 수용성 활성성분의 피부 흡수도가 향상된 수중유형 화장료 조성물의 제조방법 |
WO2004039348A1 (fr) * | 2002-10-25 | 2004-05-13 | Australian Importers, Ltd. | Formulations pour administration topique de substances bioactives et leurs procedes d'utilisation |
FR2892019A1 (fr) * | 2005-10-14 | 2007-04-20 | Oreal | Procede de traitement des rides et kit de mise en oeuvre |
WO2007020536A3 (fr) * | 2005-07-12 | 2007-07-19 | Oreal | Procede cosmetique pour le ciblage de rides |
US7393548B2 (en) * | 1999-03-22 | 2008-07-01 | J.P. M.E.D. Ltd. | Nano oil in glycerin emulsion |
WO2009085889A3 (fr) * | 2007-12-21 | 2011-03-24 | Schering-Plough Healthcare Products, Inc. | Compositions et procédés pour réduire ou empêcher la perte d'eau par la peau |
US20110319491A1 (en) * | 2008-05-30 | 2011-12-29 | Galderma Research & Development | Anhydrous depigmenting compositions comprising, within the fatty phase thereof, a solubilized phenolic compound and a retinoid |
US20120010227A1 (en) * | 2009-07-30 | 2012-01-12 | Technische Universitat Braunschweig | Formulation for nail and nail bed diseases |
US20130017160A1 (en) * | 2009-03-11 | 2013-01-17 | Isp Investments Inc. | Thickening additive compositions |
US8920821B2 (en) | 2006-04-14 | 2014-12-30 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
WO2015150694A1 (fr) | 2014-03-31 | 2015-10-08 | Arkema France | Composition cosmetique pour l'eclaircissement de la peau |
WO2015184071A1 (fr) * | 2014-05-29 | 2015-12-03 | Eveready Battery Company, Inc | Compositions cosmétiques à maintien amélioré de la couleur pour améliorer l'aspect de la peau |
US9545368B2 (en) | 2013-08-09 | 2017-01-17 | The Chemours Company Fc, Llc | Skin care compositions having cyclic diesters and methods thereof |
US20170281520A1 (en) * | 2016-03-31 | 2017-10-05 | L'oréal | Lip compositions |
US10278917B2 (en) | 2006-04-14 | 2019-05-07 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
US10639247B2 (en) | 2009-05-15 | 2020-05-05 | Merck Patent Gesellschaft | Pigment mixtures |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095209A1 (fr) | 2013-12-17 | 2015-06-25 | Mary Kay Inc. | Administration d'ingrédients actifs à la peau à partir de substances végétales |
CN107582421B (zh) * | 2017-10-17 | 2020-03-27 | 珀莱雅化妆品股份有限公司 | 一种具有抗衰老功效的化妆品用微球的制备方法 |
CN107982095B (zh) * | 2017-10-19 | 2020-03-27 | 珀莱雅化妆品股份有限公司 | 一种具有抗皱功效的缓释固体微球的制备方法 |
CN118662367A (zh) * | 2024-08-20 | 2024-09-20 | 广州芙莉莱化妆品有限公司 | 一种微凝珠护肤品及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2238242A (en) * | 1989-11-20 | 1991-05-29 | Maybe Holding Co | Mascara composition containing microspheres |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5292512A (en) * | 1988-12-20 | 1994-03-08 | Centre Internationale De Recherches Dermatologiques (C.I.R.D.) | Cosmetic or pharmaceutical composition containing microspheres of polymers or of fatty substances filled with at least one active product |
EP0610026A1 (fr) * | 1993-02-03 | 1994-08-10 | Dow Corning Corporation | Compositions cosmétiques ayant une meilleure adhérence sur la peau |
-
1996
- 1996-01-10 AR ARP960100928A patent/AR003918A1/es not_active Application Discontinuation
- 1996-01-11 EP EP96904572A patent/EP0802785A1/fr not_active Withdrawn
- 1996-01-11 BR BR9607560A patent/BR9607560A/pt not_active Application Discontinuation
- 1996-01-11 CN CN96191678A patent/CN1172426A/zh active Pending
- 1996-01-11 CA CA002209657A patent/CA2209657A1/fr not_active Abandoned
- 1996-01-11 AU AU48643/96A patent/AU4864396A/en not_active Abandoned
- 1996-01-11 PL PL96321293A patent/PL185239B1/pl unknown
- 1996-01-11 WO PCT/US1996/001560 patent/WO1996021422A1/fr not_active Application Discontinuation
- 1996-11-01 UA UA97073757A patent/UA56991C2/uk unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091171B1 (en) * | 1986-12-23 | 1995-09-26 | Ruey J Yu | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US5292512A (en) * | 1988-12-20 | 1994-03-08 | Centre Internationale De Recherches Dermatologiques (C.I.R.D.) | Cosmetic or pharmaceutical composition containing microspheres of polymers or of fatty substances filled with at least one active product |
GB2238242A (en) * | 1989-11-20 | 1991-05-29 | Maybe Holding Co | Mascara composition containing microspheres |
EP0610026A1 (fr) * | 1993-02-03 | 1994-08-10 | Dow Corning Corporation | Compositions cosmétiques ayant une meilleure adhérence sur la peau |
Non-Patent Citations (1)
Title |
---|
NOWAK G A: "DER "AHA-EFFEKT"", SOFW-JOURNAL SEIFEN, OELE, FETTE, WASCHE, vol. 119, no. 8, 8 June 1993 (1993-06-08), pages 449 - 450, XP000370085 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058628A1 (fr) * | 1997-06-20 | 1998-12-30 | Mary Kay Inc. | Composition cosmetique renfermant un agent de blanchiment et un desquamant |
WO1999058104A1 (fr) * | 1998-05-12 | 1999-11-18 | Interhealth Ab | Compositions therapeutiques |
US6406708B1 (en) | 1998-05-12 | 2002-06-18 | Interhealth Ab | Therapeutic compositions |
FR2788692A1 (fr) * | 1999-01-26 | 2000-07-28 | Oreal | Composition anhydre comprenant une phase particulaire et une phase huileuse comprenant de l'isononanoate d'isononyle, utilisation en cosmetique, pharmacie ou hygiene |
EP1023890A1 (fr) * | 1999-01-26 | 2000-08-02 | L'oreal | Composition anhydre, utilisation en cosmétique, pharmacie ou hygiéne |
US6344205B1 (en) | 1999-01-26 | 2002-02-05 | L'oreal S.A. | Anhydrous composition, cosmetic, pharmaceutical or hygiene use |
US7393548B2 (en) * | 1999-03-22 | 2008-07-01 | J.P. M.E.D. Ltd. | Nano oil in glycerin emulsion |
KR100348826B1 (ko) * | 1999-11-12 | 2002-08-17 | 주식회사 태평양 | 수용성 활성성분의 피부 흡수도가 향상된 수중유형 화장료 조성물의 제조방법 |
WO2004039348A1 (fr) * | 2002-10-25 | 2004-05-13 | Australian Importers, Ltd. | Formulations pour administration topique de substances bioactives et leurs procedes d'utilisation |
US9162084B2 (en) | 2002-10-25 | 2015-10-20 | Cellmedics, Inc. | Formulations for topical delivery of bioactive substances and methods for their use |
US7241456B2 (en) | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
WO2007020536A3 (fr) * | 2005-07-12 | 2007-07-19 | Oreal | Procede cosmetique pour le ciblage de rides |
FR2892019A1 (fr) * | 2005-10-14 | 2007-04-20 | Oreal | Procede de traitement des rides et kit de mise en oeuvre |
US10278917B2 (en) | 2006-04-14 | 2019-05-07 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
US8920821B2 (en) | 2006-04-14 | 2014-12-30 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
US11865208B2 (en) | 2006-04-14 | 2024-01-09 | Sol-Gel Technologies Ltd. | Pharmaceutical compositions comprising silica microspheres |
US10780046B2 (en) | 2006-04-14 | 2020-09-22 | Sol-Gel Technologies Ltd. | Pharmaceutical compositions comprising silica microspheres |
US9452137B2 (en) | 2006-04-14 | 2016-09-27 | Perrigo Israel Pharmaceticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
WO2009085889A3 (fr) * | 2007-12-21 | 2011-03-24 | Schering-Plough Healthcare Products, Inc. | Compositions et procédés pour réduire ou empêcher la perte d'eau par la peau |
US20110319491A1 (en) * | 2008-05-30 | 2011-12-29 | Galderma Research & Development | Anhydrous depigmenting compositions comprising, within the fatty phase thereof, a solubilized phenolic compound and a retinoid |
US20130017160A1 (en) * | 2009-03-11 | 2013-01-17 | Isp Investments Inc. | Thickening additive compositions |
US10639247B2 (en) | 2009-05-15 | 2020-05-05 | Merck Patent Gesellschaft | Pigment mixtures |
US20120010227A1 (en) * | 2009-07-30 | 2012-01-12 | Technische Universitat Braunschweig | Formulation for nail and nail bed diseases |
US9545368B2 (en) | 2013-08-09 | 2017-01-17 | The Chemours Company Fc, Llc | Skin care compositions having cyclic diesters and methods thereof |
WO2015150694A1 (fr) | 2014-03-31 | 2015-10-08 | Arkema France | Composition cosmetique pour l'eclaircissement de la peau |
WO2015184071A1 (fr) * | 2014-05-29 | 2015-12-03 | Eveready Battery Company, Inc | Compositions cosmétiques à maintien amélioré de la couleur pour améliorer l'aspect de la peau |
US11857658B2 (en) | 2014-05-29 | 2024-01-02 | Edgewell Personal Care Brands, Llc | Cosmetic compositions with enhanced color retention for improved skin appearance |
US20170281520A1 (en) * | 2016-03-31 | 2017-10-05 | L'oréal | Lip compositions |
US10744074B2 (en) * | 2016-03-31 | 2020-08-18 | L'oreal | Lip compositions |
Also Published As
Publication number | Publication date |
---|---|
BR9607560A (pt) | 1998-12-15 |
AR003918A1 (es) | 1998-09-30 |
CA2209657A1 (fr) | 1996-07-18 |
EP0802785A1 (fr) | 1997-10-29 |
PL321293A1 (en) | 1997-12-08 |
MX9705234A (es) | 1998-06-28 |
AU4864396A (en) | 1996-07-31 |
PL185239B1 (pl) | 2003-04-30 |
UA56991C2 (uk) | 2003-06-16 |
CN1172426A (zh) | 1998-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996021422A1 (fr) | Compositions cosmetiques anhydres contenant des agents actifs sur le plan dermatologique | |
US6290941B1 (en) | Powder to liquid compositions | |
DE60105246T2 (de) | Filmbildende kosmetische Zusammensetzung | |
WO1998058628A1 (fr) | Composition cosmetique renfermant un agent de blanchiment et un desquamant | |
KR101258348B1 (ko) | 장시간 지속되는 화장품 형성용 조성물 | |
JP3112436B2 (ja) | 特に、皮膚の顔貌の明るさを改良し、皺を処置するための角質溶解剤としての蜂蜜の使用 | |
CN100408021C (zh) | 皮肤外用剂 | |
HU216805B (hu) | Üreges, hőre lágyuló részecskékkel stabilizált, felületaktív anyag nélküli "olaj a vízben" emulzió és kozmetikai és/vagy dermatológiai alkalmazása | |
JP3758885B2 (ja) | 新規な顔料を含む化粧品組成物 | |
JP2004510718A (ja) | 多層角度変色ピグメントを含有する親水性連続相を有する化粧品組成物のメークアップとしての使用 | |
KR20000035348A (ko) | 폴리머 입자의 분산액 및 특정 유동제를 함유하는묻어나지 않는 화장용 조성물 | |
JPH1067640A (ja) | 架橋ポリ(2−アクリルアミド−2−メチルプロパンスルホン酸)ポリマーを含有する組成物 | |
JP2003535883A (ja) | ポリマーで構造が与えられた液体脂肪相を含む固形エマルション | |
KR20010072739A (ko) | 겔란 및 특정 계면활성제를 함유하는 o/w 에멀션 및이의 용도 | |
US20090285866A1 (en) | Self-healing polymer compositions | |
JP2007145873A (ja) | 皮膚及び/又は半粘膜の外観を変えるための、ビニルピロリドン及びアルケンのコポリマーの化粧的使用 | |
JP2000319486A (ja) | メラミン−ホルムアルデヒド樹脂または尿素−ホルムアルデヒド樹脂の粒子を含む化粧品組成物 | |
PL189774B1 (pl) | Przeciwpotowa kompozycja kosmetyczna w postaci kremu lub kompozycji na kulce | |
JP3634977B2 (ja) | 油性化粧料 | |
JP2003513998A (ja) | ゲルタイプのオイルフリー化粧品 | |
JP4181976B2 (ja) | 油性化粧料 | |
JP2004137225A (ja) | ゲル状化粧料 | |
JP2001206814A (ja) | スチレン/アクリルコポリマーを含む化粧組成物およびその使用 | |
JP2003113042A (ja) | 水中油型メ−キャップ化粧料 | |
MXPA97005234A (en) | Cosmetic compositions anhydration with agents dermatologically acti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96191678.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AZ BY KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2209657 Country of ref document: CA Ref document number: 2209657 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/005234 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996904572 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996904572 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996904572 Country of ref document: EP |